In December 2025 the U.S. Food and Drug Administration (FDA) approved Myqorzo (generic name aficamten) for the treatment of adults living with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The decision marks a major milestone in cardiovascular medicine, bringing a novel type of therapy for people facing the daily challenges of this complex genetic heart disease. For patients, caregivers, clinicians and researchers this approval has wide‑reaching implications. It expands treatment options and highlights how our understanding of heart muscle biology can lead to meaningful improvements in quality of life for people affected by oHCM.
In this post we will explore what oHCM is why the approval of Myqorzo matters how the drug works what the clinical trial data show what physicians and patients need to know about safety and dosing and what the broader future of treatment may look like.
Obstructive hypertrophic cardiomyopathy is a genetic heart condition marked by thickened heart muscle, especially in the left ventricle. This thickened muscle can block the path that blood must take to exit the heart into the aorta. As a result the heart must work harder and people often experience significant symptoms. These symptoms can include shortness of breath chest pain dizziness fainting and reduced exercise tolerance. Because of this symptom burden many individuals experience limitations in daily activities and reduced quality of life.
The estimated prevalence of hypertrophic cardiomyopathy in the United States is about 1 in 500 people, and many of these individuals have the obstructive form. The condition is often caused by variants in genes that code for structural heart proteins and can run in families. While some individuals may remain asymptomatic or develop minor symptoms early in life others experience significant issues that require long‑term monitoring and treatment.
Prior to the approval of Myqorzo therapeutic options for symptomatic oHCM focused on managing heart rate or rhythm through medications such as beta blockers and calcium channel blockers or on mechanical procedures such as surgical myectomy or alcohol septal ablation to reduce obstruction. These approaches improved symptoms for many patients but did not directly target the underlying mechanics of excessive muscle contraction that characterize this condition.
Myqorzo is part of a new class of targeted therapies known as cardiac myosin inhibitors. It acts by reducing the force of contraction of heart muscle cells. Myosin proteins are central to the contraction process inside heart cells. By selectively inhibiting these motor proteins Myqorzo helps decrease the strength of contraction and lessen the left ventricular outflow tract obstruction that contributes to symptoms in people with oHCM. This approach addresses a fundamental aspect of disease physiology rather than only treating symptoms.
The drug’s action is allosteric and reversible, meaning it binds to the myosin protein in a way that can be modulated and adjusted if needed. The FDA approval includes multiple tablet strengths including 5 mg 10 mg 15 mg and 20 mg to give physicians flexibility in dosing based on individual patient needs.
Another notable feature of Myqorzo is that unlike some previous therapies it does not require specialized monitoring for interactions with other drugs. This characteristic may simplify use in clinical practice.
The FDA approval of Myqorzo was based on results from a pivotal Phase 3 clinical trial called SEQUOIA‑HCM. This study was designed to measure how well Myqorzo improves exercise capacity and reduces symptoms in adult patients with symptomatic oHCM compared with placebo.
In the trial people taking Myqorzo for 24 weeks experienced significant improvements in exercise tolerance measured by peak oxygen uptake (pVO2) during cardiopulmonary exercise testing (CPET). The difference between patients taking Myqorzo and those taking placebo was robust and statistically significant indicating a real benefit in functional capacity that can translate to everyday life improvements for patients.
The treatment effect was consistent across a range of patient subgroups including different ages sexes and baseline treatment backgrounds. It was also observed in patients whether or not they were on background therapy with other medications such as beta blockers. These results build confidence that a wide range of patients with oHCM could benefit from the therapy.
In addition to improving exercise capacity the trial data showed reductions in patient‑reported symptoms. These improvements address not only measurable clinical outcomes but also how patients feel and function on a daily basis.
While Myqorzo offers a promising new option for treating oHCM it also comes with specific safety considerations. Because the drug reduces cardiac contractility it can lower left ventricular ejection fraction, which in some cases could lead to heart failure if not carefully monitored. For this reason the FDA has approved Myqorzo under a Risk Evaluation and Mitigation Strategy (REMS). This program helps ensure that patients receive careful evaluation and follow‑up during treatment.
Clinicians are advised to assess cardiac function with imaging studies before starting therapy and at intervals during treatment. If left ventricular ejection fraction drops below certain thresholds treatment may need to be adjusted or interrupted to protect patient safety.
In clinical trials Myqorzo was generally well tolerated. The safety profile was considered favorable overall with low rates of serious adverse events. Some patients experienced changes in blood pressure and other symptoms consistent with the mechanism of action but these events were manageable with proper clinical oversight.
As of December 19 2025 the FDA approved Myqorzo for adults with symptomatic oHCM to improve functional capacity and symptoms. This approval makes Myqorzo the first FDA‑approved product from Cytokinetics and only the second cardiac myosin inhibitor approved in the United States for this indication after a previous drug in the same class.
Beyond the U.S. regulatory landscape Myqorzo is also progressing in international approvals. A positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has been adopted recommending marketing authorization in the European Union, with a final decision expected in the first quarter of 2026.
In China the National Medical Products Administration has already approved Myqorzo for treatment of adults with oHCM in December 2025, triggering milestone payments under licensing agreements and expanding access to patients in that region.
Historically the FDA had previously accepted the New Drug Application and set target action dates for review as part of a standard regulatory process, reflecting a multi‑year effort to bring this therapy to patients.
Before Myqorzo was approved physicians relied on traditional medications and invasive procedures to manage oHCM symptoms. Beta blockers and calcium channel blockers helped by reducing heart rate and easing symptoms but did not directly target cardiac myosin or the underlying hypercontractility of the muscle. Procedures like surgical myectomy and alcohol septal ablation remain important options for some patients but involve surgery and recovery with variable patient experience.
Myqorzo adds a new mechanism of action that complements these existing strategies. Its design aimed for predictable pharmacology and a flexible dosing regimen which may make it more convenient for many patients compared to earlier agents. Because it addresses core disease mechanics rather than only symptom control many physicians see it as a meaningful advance in care.
In addition greater real‑world experience after commercial launch will help clinicians understand how best to integrate Myqorzo into comprehensive patient management. Some patients may still require procedures or other medications depending on individual health profiles but the presence of a targeted oral therapy expands clinical choice.
If you are living with obstructive hypertrophic cardiomyopathy and your clinician is considering Myqorzo as a treatment option here are key points to discuss:
Many patients and advocacy groups have welcomed the approval as an important moment in oHCM care because it provides a new way to target the disease process itself. For people managing limitations in day‑to‑day activity due to symptoms this can be life‑changing.
The approval of Myqorzo represents a broader shift toward precision medicine in cardiology, where targeted therapies are developed to interact with specific disease mechanisms. Ongoing research is investigating whether cardiac myosin inhibitors like aficamten may also benefit other forms of hypertrophic cardiomyopathy or additional heart muscle diseases.
Long‑term outcomes and real‑world experience will continue to inform how this therapy is used most effectively and how it affects patient outcomes over years rather than months. Researchers are also exploring other next‑generation molecules and combination strategies to further improve therapy for heart disease.
The FDA approval of Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy marks a significant advance in the treatment of this complex condition. By targeting cardiac myosin activity to reduce harmful muscle hypercontractility and improve blood flow Myqorzo offers a new therapeutic option backed by rigorous clinical evidence. Patients and clinicians can now consider a targeted oral therapy with the potential to improve exercise capacity and symptoms for many people affected by oHCM. With ongoing global regulatory progress research and clinical adoption this approval represents an important step forward in heart disease management.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.